Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Platelet activity and selective beta-blockade in migraine prophylaxis.

R Joseph1, T J Steiner, L U Schultz

  • 1Princess Margaret Migraine Clinic, Charing Cross Hospital, London, United Kingdom.

Stroke
|June 1, 1988
PubMed
Summary

Beta-blockers for migraine prophylaxis can affect platelet activity. Beta 1-selective blockers like metoprolol reduce platelet aggregation, making them preferable to nonselective agents for migraine treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intra-host SARS-CoV-2 diversity in immunocompromised people living with HIV provides insight into the evolutionary trajectory of SARS-CoV-2.

Journal of virology·2025
Same author

Ultrasound-guided intraparenchymal injection of slow release Chondroitinase ABC-37 in the chronic phase of spinal cord injury improves long-term recovery.

Experimental neurology·2025
Same author

First Proton-Induced Cross Sections on a Stored Rare Ion Beam: Measurement of ^{118}Te(p,γ) for Explosive Nucleosynthesis.

Physical review letters·2025
Same author

Nuclear Astrophysics in the Storage Ring: Background Suppressed Simultaneous Measurement of (p,γ) and (p,n) Reactions.

Physical review letters·2025
Same author

Measurement of the Isolated Nuclear Two-Photon Decay in ^{72}Ge.

Physical review letters·2024
Same author

Frequency, kinetics and determinants of viable SARS-CoV-2 in bioaerosols from ambulatory COVID-19 patients infected with the Beta, Delta or Omicron variants.

Nature communications·2024

Area of Science:

  • Pharmacology and Neurology
  • Cardiovascular Research

Background:

  • Migraine is linked to heightened platelet activity and increased risk of cerebrovascular ischemic events.
  • Beta-adrenoceptor blockers, such as propranolol and metoprolol, are used for migraine prophylaxis, but their effects on platelet behavior in migraine patients are not fully understood.
  • Understanding beta-receptor subtype selectivity's impact on platelet function is crucial for optimizing migraine treatment.

Purpose of the Study:

  • To investigate the influence of beta-receptor subtype selectivity of beta-blockers on platelet aggregation and adenosine triphosphate (ATP) release in migraine patients.
  • To compare the effects of nonselective (propranolol), beta 1-selective (metoprolol), and beta 2-selective (Li 32-468) beta-blockers on platelet activity.

Main Methods:

  • A study involving 29 migraine patients treated for one month with therapeutic doses of propranolol, metoprolol, or Li 32-468.

Related Experiment Videos

  • Assessment of clinical responses to ensure comparable efficacy across treatments.
  • Measurement of platelet aggregation and adenosine triphosphate (ATP) release to evaluate drug effects on platelet function.

    • Main Results:

    • Propranolol was found to increase platelet aggregation and ATP release, while metoprolol decreased these parameters.
    • The beta 2-selective agent, Li 32-468, showed effects on platelet activity that were comparable to propranolol.
    • These observed platelet actions are consistent with known platelet beta-receptor pharmacology and can likely be generalized to other effective beta-blockers.

    Conclusions:

    • The efficacy of these beta-blockers in migraine prophylaxis is not attributable to altered platelet activity.
    • The effects of beta-blockers on platelet function should be considered as potential side effects.
    • Beta-blockers that inhibit platelet activity, such as beta 1-selective agents like metoprolol, are preferable for migraine treatment, assuming equivalent clinical efficacy.